· Published by Health Canada · Official notice
This is duplicated text of a letter from Biogen Idec Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
Public Communication
Health Canada Endorsed Important Safety Information on TYSABRI™ (natalizumab)
June 2, 2008
Subject: Reports of liver injury and allergic reactions with TYSABRI™ (natalizumab)
Following discussions with Health Canada, Biogen Idec wishes to provide you with important new safety information regarding the risk of liver injury and allergic reactions in patients receiving TYSABRI™. This communication is also notifying you of updated safety information on herpes infections.
TYSABRI™ is used to treat patients with a form of multiple sclerosis called relapsing-remitting (periods of symptoms alternating with periods without symptoms).
Liver Problems:
Allergic Reactions:
Patients should call their doctor right away if they experience any of the following signs and symptoms:
Liver Problems:
Allergic Reactions:
Herpes Infections:
This advisory is in addition to a letter issued to health care professionals concerning the same information. The letter can be found on Health Canada's website.
The Canadian prescribing information for TYSABRI™ has been updated to include new information in the Warnings and Precautions for liver problems and allergic reactions and in the Adverse Reaction section and Consumer Information section for herpes infections. The prescribing information is available by contacting the Tysabri Care Program™.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious liver symptoms or other serious or unexpected adverse reactions in patients receiving TYSABRI™ should be reported to the Tysabri Care Program™ or Health Canada at the following addresses:
Tysabri Care Program™
Phone: 1-888-827-2827
Biogen Idec Canada Inc.
3 Robert Speck Parkway, Suite 300
Mississauga, ON L4Z 2G5
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorat
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Dr. Len Walt, M.D., M.B.A.
Medical Director